Mary Kate Kelly1, Robert W Grundmeier2, Alisa J Stephens-Shields3, Russell Localio3, Laura P Shone4, Margaret Wright4, Jennifer Steffes4, Sharon G Humiston5, Cynthia Rand6, Christina Albertin7, Abigail Breck7, Dianna E Abney8, Greta McFarland8, Peter G Szilagyi6, Alexander G Fiks9. 1. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, United States. 2. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, United States. 3. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. 4. Primary Care Research, American Academy of Pediatrics, Itasca, IL, United States; Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca, IL, United States. 5. Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, United States. 6. Department of Pediatrics, University of Rochester, Rochester, NY, United States. 7. Department of Pediatrics, University of California Los Angeles Mattel Children's Hospital, Los Angeles, CA, United States. 8. Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca, IL, United States. 9. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca, IL, United States. Electronic address: fiks@email.chop.edu.
Abstract
INTRODUCTION: Little is known about missed opportunities (MOs) for HPV vaccination during primary care visits at which influenza vaccination is delivered. METHODS: We extracted electronic health records for HPV vaccine-eligible 11-to-17-year-olds. We assessed the proportion of visits during which an influenza vaccine was given and an HPV vaccine was due, but not given (i.e., MOs). RESULTS: Of 56,135 eligible visits, 57.5% represented MOs for HPV vaccination. MOs were more common at visits where an initial versus subsequent HPV vaccine dose was due (68.6% vs. 31.3%) and for acute/chronic and nurse-only visits compared to preventive visits (74.0% and 80.2% vs. 36.7%). In a multivariable model, MOs were more likely for the initial HPV dose and for non-preventive visits, but did not vary by patient sex/age. CONCLUSIONS: HPV vaccine MOs were common during visits where influenza vaccine was administered. Increasing simultaneous administration of HPV and influenza vaccines could increase HPV vaccine coverage.
INTRODUCTION: Little is known about missed opportunities (MOs) for HPV vaccination during primary care visits at which influenza vaccination is delivered. METHODS: We extracted electronic health records for HPV vaccine-eligible 11-to-17-year-olds. We assessed the proportion of visits during which an influenza vaccine was given and an HPV vaccine was due, but not given (i.e., MOs). RESULTS: Of 56,135 eligible visits, 57.5% represented MOs for HPV vaccination. MOs were more common at visits where an initial versus subsequent HPV vaccine dose was due (68.6% vs. 31.3%) and for acute/chronic and nurse-only visits compared to preventive visits (74.0% and 80.2% vs. 36.7%). In a multivariable model, MOs were more likely for the initial HPV dose and for non-preventive visits, but did not vary by patient sex/age. CONCLUSIONS:HPV vaccine MOs were common during visits where influenza vaccine was administered. Increasing simultaneous administration of HPV and influenza vaccines could increase HPV vaccine coverage.
Authors: Edson D Moreira; Stan L Block; Daron Ferris; Anna R Giuliano; Ole-Erik Iversen; Elmar A Joura; Pope Kosalaraksa; Andrea Schilling; Pierre Van Damme; Jacob Bornstein; F Xavier Bosch; Sophie Pils; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Hong Qi; Donna Hyatt; Jason Martin; Erin Moeller; Michael Ritter; Martine Baudin; Alain Luxembourg Journal: Pediatrics Date: 2016-07-15 Impact factor: 7.124
Authors: X Castellsagué; A R Giuliano; S Goldstone; A Guevara; O Mogensen; J M Palefsky; T Group; C Shields; K Liu; R Maansson; A Luxembourg; S S Kaplan Journal: Vaccine Date: 2015-07-02 Impact factor: 3.641
Authors: Stephanie A Irving; Holly C Groom; Shannon Stokley; Michael M McNeil; Julianne Gee; Ning Smith; Allison L Naleway Journal: Acad Pediatr Date: 2018-03 Impact factor: 3.107
Authors: Grace Ryan; Sato Ashida; Paul A Gilbert; Aaron Scherer; Mary E Charlton; Amanda Kahl; Natoshia Askelson Journal: J Community Health Date: 2022-06-17
Authors: Grace W Ryan; Sarah S Perry; Aaron Scherer; Mary E Charlton; Sato Ashida; Paul A Gilbert; Natoshia Askelson Journal: Vaccine X Date: 2022-07-09